A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

589

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Non-small Cell Lung AdenocarcinomaSquamous Cell Carcinoma of Lung

Interventions

DRUG

SI-B001

Administration by intravenous infusion

DRUG

Docetaxel

Administration by intravenous infusion

Trial Locations (2)

Sun Yat-sen University Cancer Center, Guangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY